Drugs / von Hippel-Lindau peptide vaccine
von Hippel-Lindau peptide vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00001703 | Aug 1998 → Nov 2008 | renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | von Hippel-Lindau peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001703 ↗ |
| Modality | Vaccine | “corresponding mutant VHL peptide vaccination” NCT00001703 ↗ |
| Route | Subcutaneous | “Patients are vaccinated with 1000 micrograms of the mutant Von Hipple-Lindau (VHL) peptide administered subcutaneously” NCT00001703 ↗ |
| Target | VHL | “test whether VHL tumor suppressor protein can be immunologically targeted by vaccination” NCT00001703 ↗ |